Sign in
Active, not recruitingPhase 4

Thymosin Alpha 1 and IgM Levels in Sepsis

Key facts

Who runs it
Southeast University, China
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Phase 4
People taking part
36 people, planned
Started
20 Feb 2026
Expected to end
31 Jan 2027
Type of study
Interventional
Treatments tested
  • Thymalfasin
Record updated
6 November 2026

Who can take part

Age
18 years to 85 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Adults aged 18 to 85 years
  • Admitted to the Department of Critical Care Medicine, Zhongda Hospital Southeast University, with sepsis diagnosed according to the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3.0): confirmed or highly suspected infection with an acute increase in Sequential Organ Failure Assessment (SOFA) score of at least 2 points from baseline
  • Written informed consent provided by the participant or legally authorized representative

Who cannot take part

  • Previous solid organ or bone marrow transplantation
  • Treatment within the past 30 days with immunosuppressive drugs (for example, tripterygium wilfordii, mycophenolate mofetil, cyclophosphamide, or tacrolimus) or continuous treatment with more than 10 mg/day prednisolone or an equivalent dose of another corticosteroid
  • Use of thymosin drugs within the past 30 days or participation in another clinical study of a drug or device affecting immunity (for example, Xuebijing, ulinastatin, or continuous renal replacement therapy)
  • Current or previous B-cell lymphoma, multiple myeloma, or leukemia
  • Active connective tissue disease (for example, rheumatoid disease or systemic lupus erythematosus) or glomerulonephritis
  • Current malignancy
  • History of allergy or intolerance to thymalfasin
  • Pregnancy or lactation
  • Expected survival of less than 72 hours or a decision to receive restricted life-support treatment (comfort care only)

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This prospective, single-arm study will evaluate whether thymosin alpha 1 treatment affects serum immunoglobulin M (IgM) levels in adults with sepsis. Participants will receive standard care plus thymosin alpha 1 1.6 mg by subcutaneous injection every 12 hours for 5 days. Blood samples will be collected before treatment and on days 1, 3, 5, and 7 to measure IgM and plasma microvesicles. The study aims to clarify whether thymosin alpha 1 may support early immune responses in sepsis.

The group in the trial

  • Thymosin alpha 1 treatment groupTreatment being tested

    Adults with sepsis receiving standard clinical care plus thymosin alpha 1 1.6 mg subcutaneously every 12 hours for 5 days.

    Treatment: Thymalfasin

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Exploring the Correlation Between Thymosin Alpha 1 and IgM Levels in Sepsis Patients
Record updated
6 November 2026